Subarachnoid Hemorrhage, AneurysmalFAPPAR-HSANCT07508683
Pronostic Factors in Elderly Patients Admitted to the Intensive Care Unit for Aneurysmal Subarachnoid Hemorrhage
An observational study of Subarachnoid Hemorrhage, Aneurysmal, run by Central Hospital, Nancy, France at 1 site in France.
Trial summary
Subarachnoid hemorrhage (SAH) represents a significant proportion of hemorrhagic strokes. Severe SAH in elderly patients is associated with poorer outcomes compared to younger cohorts. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Subarachnoid Hemorrhage, Aneurysmal
- How many people
- 170 participants
- Where
- 1 siteFrance
- Study dates
- May 2026to Mar 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adult patients admitted in ICU for aneurysmal subarachnoid hemorrhage in 4 University Hospital Centers in France (CHU Nancy, CHU Reims, HC de Lyon, CHU Lille) between Juin 30, 2021 et Juin 30, 2025
Who may be able to join
- Patients hospitalized in ICU for aneurysmal subarachnoid hemorrhage
- Aged 70 years or over the day of admission in ICU
- Between Juin 30, 2021 and Juin 30, 2025
Who cannot join
- Decline to participate
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site
Chru Nancy
Nancy, 54000
Ionel M ALB, MD, 0033-661028367, im.alb@chru-nancy.fr
Ionel M ALB, MD
About this study
Official title: Pronostic Factors in Elderly Patients Admitted to the Intensive Care Unit for Aneurysmal Subarachnoid Hemorrhage Multicenter Retrospective Observational Study FAPPAR-HSA
Subarachnoid hemorrhage (SAH) represents a significant proportion of hemorrhagic strokes. Severe SAH in elderly patients is associated with poorer outcomes compared to younger cohorts. Better characterization of both short- and long -term prognosis in these patients is necessary to facilitate medical decision-making in the intensive care unit (ICU)
Primary Objective:
Read more
The primary objective is to identify prognostic factors associated with poor functional outcome or death at 6 months (± 2 months) in elderly patients admitted to the ICU for SAH.
Secondary Objectives:
To evaluate in-hospital mortality among elderly patients admitted to the ICU for SAH.
To describe the causes of in-hospital death (brain death, withholding/withdrawal of life-sustaining treatment [WOLST], other medico-surgical causes) in elderly patients admitted to the ICU for SAH.
To describe the care trajectory following hospital discharge for elderly patients admitted to the ICU for SAH.
To evaluate the mean length of stay in the ICU and in the hospital (acute care) for elderly patients admitted to the ICU for SAH.
To identify prognostic factors associated with poor functional outcome or death at 1 year in elderly patients admitted to the ICU for SAH.
- Conditions
- Subarachnoid Hemorrhage, Aneurysmal
- Keywords
- Subarachnoid Hemorrhage, Elderly, Prognostic Factors, Intensive Care Unit
- Medical subject headings
- Subarachnoid Hemorrhage
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Elderly aneurysmal SAH patients hospitalized in ICU | Patients hospitalized in ICU for aneurysmal subarachnoid hemorrhage between Juin 30, 2021 and Juin 30, 2025. Aged 70 years or over the day of admission in ICU. In accordance with French regulations , the study included patients who did not object to the use of their clinical data after receiving written information. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Modified Rankin Scale (MRS) et 6 months
MRS : scale from 1(no symptoms) to 6 (dead) Good outcome : 0 - 2 Bad outcome: 3 - 6 The MRS grade is either collected if already available in the medical file or estimated retrospectively based on the patient neurological evaluation.
Measured: 6 months after ICU discharge
Secondary outcomes (4)
Intrahospital mortality
Intrahospital mortality = percentage of deaths occuring during the initial hospitalisation (in the ICU and the neurosurgical/neurological ward)
Measured: Day 28
Cause of intrahospital death
Percentage of the following categories: cerebral death, WOLST, surgical causes and medical causes
Measured: Day 28
Destination upon hospital discharge
Percentage of the following categories: Discharge to Home versus Rehabilitation Unit versus Another Inpatient Ward (non-neurosurgical)
Measured: Day 28
Modified Rankin Scale upon discharge from hospital.
MRS retrieved or estimated from patient's file data at the moment of ICU or neurosurgical ward discharge.
Measured: Day 28
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Apr 2026
- Study startMay 2026 (estimated)
- Primary completionNov 2026 (estimated)
- Study completionMar 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Subarachnoid Hemorrhage, AneurysmalStudies of the same condition, open and under way.
- More trials run by Central Hospital, Nancy, FranceThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 170 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Central Hospital, Nancy, France
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, ALB Ionel mircea, Central Hospital, Nancy, France
- Investigators
- Viviane MARTIN, Chief of Research Departement, Study chair, CHRU NANCY, DRCIElodie JEANBERT, Methodologist, Statistician, Study chair, CHRU NANCY, DRCI
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07508683
- Sponsor's protocol ID
- 2025PI114
- Acronym
- FAPPAR-HSA
- Status last verified
- Mar 2026
- First submitted
- 16 Mar 2026
- Last updated
- 2 Apr 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pronostic Factors in Elderly Patients Admitted to the Intensive Care Unit for Aneurysmal Subarachnoid Hemorrhage Multicenter Retrospective Observational Study FAPPAR-HSA
- ClinicalTrials.gov ID
- NCT07508683
- Acronym / sponsor ID
- FAPPAR-HSA / 2025PI114
- Conditions
- Subarachnoid Hemorrhage, Aneurysmal
- Keywords
- Subarachnoid Hemorrhage, Elderly, Prognostic Factors, Intensive Care Unit
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 170 participants (estimated)
- Lead sponsor
- Central Hospital, Nancy, FranceUniversity, hospital or other
- Study start
- May 2026 (estimated)
- Primary completion
- Nov 2026 (estimated)
- Study completion
- Mar 2027 (estimated)
- First posted
- 2 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Subarachnoid hemorrhage (SAH) represents a significant proportion of hemorrhagic strokes. Severe SAH in elderly patients is associated with poorer outcomes compared to younger cohorts. Better characterization of both short- and long -term prognosis in these patients is necessary to facilitate medical decision-making in the intensive care unit (ICU)
Primary Objective:
The primary objective is to identify prognostic factors associated with poor functional outcome or death at 6 months (± 2 months) in elderly patients admitted to the ICU for SAH.
Secondary Objectives:
To evaluate in-hospital mortality among elderly patients admitted to the ICU for SAH.
To describe the causes of in-hospital death (brain death, withholding/withdrawal of life-sustaining treatment [WOLST], other medico-surgical causes) in elderly patients admitted to the ICU for SAH.
To describe the care trajectory following hospital discharge for elderly patients admitted to the ICU for SAH.
To evaluate the mean length of stay in the ICU and in the hospital (acute care) for elderly patients admitted to the ICU for SAH.
To identify prognostic factors associated with poor functional outcome or death at 1 year in elderly patients admitted to the ICU for SAH.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Elderly aneurysmal SAH patients hospitalized in ICU | – | –Patients hospitalized in ICU for aneurysmal subarachnoid hemorrhage between Juin 30, 2021 and Juin 30, 2025. Aged 70 years or over the day of admission in ICU. In accordance with French regulations , the study included patients who did not object to the use of their clinical data after receiving written information. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adult patients admitted in ICU for aneurysmal subarachnoid hemorrhage in 4 University Hospital Centers in France (CHU Nancy, CHU Reims, HC de Lyon, CHU Lille) between Juin 30, 2021 et Juin 30, 2025
Key inclusion criteria (3 listed)
- Patients hospitalized in ICU for aneurysmal subarachnoid hemorrhage
- Aged 70 years or over the day of admission in ICU
- Between Juin 30, 2021 and Juin 30, 2025
Key exclusion criteria (1 listed)
- Decline to participate
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Modified Rankin Scale (MRS) et 6 months
Time frame: 6 months after ICU discharge
MRS : scale from 1(no symptoms) to 6 (dead) Good outcome : 0 - 2 Bad outcome: 3 - 6 The MRS grade is either collected if already available in the medical file or estimated retrospectively based on the patient neurological evaluation.
4 secondary outcomes
Intrahospital mortality
Time frame: Day 28
Cause of intrahospital death
Time frame: Day 28
Destination upon hospital discharge
Time frame: Day 28
Modified Rankin Scale upon discharge from hospital.
Time frame: Day 28
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Apr 2026.
Related trials for Subarachnoid Hemorrhage, Aneurysmal
Not yet recruitingPhase 3
TicAgreLor Versus Placebo to Prevent Cerebral ISCHemia in anEuRysmal Low Grade SAH A Double Blinded Randomised Controlled Study
Subarachnoid Hemorrhage, Aneurysmal, Brain Ischemia
Recruiting
Early Motor-Cognitive Integrative Training on Cognitive and Motor Performance in Patients With Aneurysmal Subarachnoid Hemorrhage
Subarachnoid Aneurysm Hemorrhage
RecruitingObservational study
Determining the Clinical Impact and Prevalence of Hemorrhagic Subtypes in Perimesencephalic Subarachnoid Hemorrhage
Subarachnoid Hemorrhage, Spontaneous, Subarachnoid Hemorrhage, Aneurysmal
Not yet recruitingPhase 1/2
Induced Suppression of Platelet Activity in Aneurysmal Subarachnoid Hemorrhage Management-2 (iSPASM-2)
Aneurysmal Subarachnoid Hemorrhage
RecruitingPhase 2
Infusion of Lidocaine and Steroids in Middle Meningeal Artery for Pain in Subarachnoid Hemorrhage
Subarachnoid Hemorrhage, Aneurysmal, Headache
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Viviane MARTIN, Chief of Research Departement study chair
CHRU NANCY, DRCI
Elodie JEANBERT, Methodologist, Statistician study chair
CHRU NANCY, DRCI
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Subarachnoid Hemorrhage, Aneurysmal, run by Central Hospital, Nancy, France at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 2 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Ionel M ALB, MD Intensive Care/Anesthesia (0033-661028367, im.alb@chru-nancy.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Modified Rankin Scale (MRS) et 6 months (time frame: 6 months after ICU discharge). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Apr 2026.